相关临床试验
16
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
18.8%
已完成
10
62.5%
招募中
3
18.8%
暂无批准数据
- Osivax received $19.5 million in funding from BARDA to accelerate development of OVX836, a next-generation broad-spectrum influenza A vaccine candidate. - The vaccine targets the highly conserved nucleoprotein of influenza virus, potentially providing universal protection against current and future strains. - OVX836 has been tested in 7 clinical trials with over 1,400 participants, demonstrating promising safety, immunogenicity, and efficacy results. - The funding will support ongoing clinical development, large-scale trial preparation, and manufacturing scale-up activities.
- Osivax announced completion of patient visits in its Phase 2a booster trial evaluating OVX836, a broad-spectrum influenza A vaccine candidate targeting the highly conserved nucleoprotein antigen. - The randomized, double-blind trial enrolled 117 healthy adults aged 20-64 who previously participated in Phase 2 trials conducted 3-5 years ago, testing booster doses at 180μg or 480μg. - OVX836 represents a first-in-class approach using oligoDOM™ nanoparticle technology to target the nucleoprotein, which is less likely to mutate than surface antigens. - Final results are expected in the second half of 2025, with the trial uniquely assessing immune response persistence and boostability over an extended timeframe.
- Osivax secures €10 million in Series B financing, with strategic investment from Japanese pharmaceutical leader Meiji Seika Pharma, to accelerate development of broad-spectrum influenza vaccine candidates. - The company's lead candidate OVX836 is progressing to a Phase 2b field efficacy study involving 2,850 participants across multiple international sites. - Osivax's innovative oligoDOM™ platform technology aims to generate superior T-cell and B-cell responses for comprehensive protection against respiratory viruses.
- Osivax has dosed the first participant in a Phase 2a clinical trial evaluating OVX836 as a booster for its broad-spectrum influenza vaccine candidate. - The trial assesses the safety and immunogenicity of a booster dose in participants previously vaccinated with OVX836 three to five years prior. - OVX836 targets the nucleoprotein, a conserved internal antigen of influenza A, aiming for a broader and more universal immune response. - Topline results from the randomized, double-blind study, conducted at Ghent University Hospital, are expected by the end of 2025.
